Comparative efficacy and acceptability of pharmacological interventions for the treatment and prevention of delirium: A systematic review and network meta-analysis.
Antipsychotics
Delirium
Dexmedetomidine
Intensive care unit
Network meta-analysis
Ramelteon
Journal
Journal of psychiatric research
ISSN: 1879-1379
Titre abrégé: J Psychiatr Res
Pays: England
ID NLM: 0376331
Informations de publication
Date de publication:
06 2020
06 2020
Historique:
received:
19
11
2019
revised:
03
03
2020
accepted:
23
03
2020
pubmed:
18
4
2020
medline:
15
5
2021
entrez:
18
4
2020
Statut:
ppublish
Résumé
We performed a network meta-analysis to build clear hierarchies of efficacy and tolerability of pharmacological interventions for the treatment and prevention of delirium. Electronic databases including PubMed, Google Scholar, Embase, Cochrane Central Register of Controlled Trials, PsycINFO, and MEDLINE were searched published up to February 22, 2019. A total of 108 randomized controlled trials (RCTs) investigating pharmacotherapy on delirium were included for analysis, and the strength of evidence (SoE) was evaluated for critical outcomes. In terms of treatment, quetiapine (low SoE), morphine (low SoE), and dexmedetomidine (moderate SoE) were effective in the intensive care unit (ICU) patients. In terms of prevention, dexmedetomidine (high SoE) and risperidone (high SoE) significantly reduced the incidence of delirium in ICU surgical patients, while ramelteon (high SoE) reduced the incidence of delirium in ICU medical patients. Despite the efficacy, dexmedetomidine and risperidone demonstrated higher drop-out rate (moderate to high SoE). Haloperidol and other antipsychotics, except for quetiapine and risperidone, showed no benefit. None of the agents showed benefit in non-ICU patients. In conclusion, dexmedetomidine may be a drug of choice for both treating and preventing delirium of the ICU and postsurgical patients. However, it may be less tolerable, and side-effects should be adequately managed. Current evidence does not support the routine use of antipsychotics. For medical patients, oral ramelteon might be useful for prevention.
Identifiants
pubmed: 32302794
pii: S0022-3956(19)31287-7
doi: 10.1016/j.jpsychires.2020.03.012
pii:
doi:
Substances chimiques
Antipsychotic Agents
0
Haloperidol
J6292F8L3D
Risperidone
L6UH7ZF8HC
Types de publication
Journal Article
Meta-Analysis
Research Support, Non-U.S. Gov't
Review
Systematic Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
164-176Informations de copyright
Copyright © 2020 Elsevier Ltd. All rights reserved.
Déclaration de conflit d'intérêts
Declaration of competing interest Min Seo Kim, Hye Chang Rhim, Ariel Park, Hanna Kim, Kyu-Man Han, Ashwin A. Patkar, Chi-Un Pae, and Changsu Han have no commercial associations that may present a conflict of interest in relation to this manuscript.